- Home
- REFR vs BCAB Comparison
REFR vs BCAB Comparison
Compare REFR & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- BCAB
- Stock Information
- Founded
- REFR 1965
- BCAB 2007
- Country
- REFR United States
- BCAB United States
- Employees
- REFR N/A
- BCAB N/A
- Industry
- REFR Multi-Sector Companies
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- REFR Miscellaneous
- BCAB Health Care
- Exchange
- REFR Nasdaq
- BCAB Nasdaq
- Market Cap
- REFR 67.4M
- BCAB 77.8M
- IPO Year
- REFR N/A
- BCAB 2020
- Fundamental
- Price
- REFR $1.71
- BCAB $1.25
- Analyst Decision
- REFR
- BCAB Buy
- Analyst Count
- REFR 0
- BCAB 2
- Target Price
- REFR N/A
- BCAB $5.00
- AVG Volume (30 Days)
- REFR 25.1K
- BCAB 645.3K
- Earning Date
- REFR 11-07-2024
- BCAB 11-07-2024
- Dividend Yield
- REFR N/A
- BCAB N/A
- EPS Growth
- REFR N/A
- BCAB N/A
- EPS
- REFR N/A
- BCAB N/A
- Revenue
- REFR $1,469,616.00
- BCAB $11,000,000.00
- Revenue This Year
- REFR N/A
- BCAB N/A
- Revenue Next Year
- REFR N/A
- BCAB N/A
- P/E Ratio
- REFR N/A
- BCAB N/A
- Revenue Growth
- REFR 102.07
- BCAB N/A
- 52 Week Low
- REFR $0.91
- BCAB $1.14
- 52 Week High
- REFR $2.41
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- REFR 26.45
- BCAB 33.19
- Support Level
- REFR $1.68
- BCAB $1.28
- Resistance Level
- REFR $1.95
- BCAB $1.72
- Average True Range (ATR)
- REFR 0.09
- BCAB 0.10
- MACD
- REFR -0.01
- BCAB -0.02
- Stochastic Oscillator
- REFR 8.60
- BCAB 4.35
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. Its revenue source comes from the licensing of technology.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.